Over 75% of CDF drugs reappraised by NICE now approved for routine use

17 November 2016

More than 75% of treatments in the UK’s Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS.

The cost-effectiveness watchdog for England and Wales has been reappraising cancer drugs which had not been recommended in previous NICE guidance (11 drug indications in total), and were only available to patients through the CDF. Out of nine treatments the NICE has looked at so far, seven have been approved in either final or draft guidance. The remainder are in the process of being reappraised.

NICE draft guidance published today means that dasatinib (Sprycel, from Bristol-Myers Squibb [NYSE: BMY]) for two indications of Philadelphia-chromosome-positive chronic myeloid leukemia can come off the CDF and be routinely available to patients on the National Health Service – which brings the total of approved reappraised CDF treatments to seven.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK